Cargando…

163 HIV and kidney function with a focus on traditional risk factors and role of TDF, PI and other medication

No abstract provided.

Detalles Bibliográficos
Autor principal:	Mallon, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JAIDS Journal of Acquired Immune Deficiency Syndromes 2014
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149643/ http://dx.doi.org/10.1097/01.qai.0000446747.07226.db

Ejemplares similares

337. Switching from TDF to TAF: Missed Opportunities for Statin Use in HIV
por: Mallon, Patrick, et al.
Publicado: (2019)

2258. Clinical Predictors of Acute Kidney Injury in HIV Infected Patients Treated With Tenofovir Disoproxil Fumarate (TDF)
por: Holleman, Don, et al.
Publicado: (2018)

Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years
por: Gazzard, Brian, et al.
Publicado: (2014)

1298. Acquisition of TDF-Susceptible HIV Despite High Level Adherence to Daily TDF/FTC PrEP as Measured by Dried Blood Spot (DBS) and Segmental Hair Analysis: A Case Report
por: Cohen, Stephanie E, et al.
Publicado: (2018)

979. BMI and ASCVD Risk Score Changes in Virologically Suppressed Patients with HIV Switching from TDF to TAF Containing ART
por: Schafer, Jason J, et al.
Publicado: (2019)

995. Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline
por: Campbell, Thomas, et al.
Publicado: (2020)

TDF (Theoretical Domain Framework): how inclusive are TDF domains and constructs compared to other tools for assessing barriers to change?
por: Sarmast, Hamideh, et al.
Publicado: (2014)

1962. Renal Outcomes for Participants Taking F/TAF vs. F/TDF for HIV PrEP in the DISCOVER Trial
por: Mills, Anthony, et al.
Publicado: (2019)

103. Persistence on F/TDF for HIV Pre-exposure Prophylaxis: Insights from Real-world Evidence
por: Tao, Li, et al.
Publicado: (2020)

T163. Submission Withdrawn
Publicado: (2018)

Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis
por: Arribas, Jose, et al.
Publicado: (2014)

2259. Effect of Discontinuation of Tenofovir Disoproxil Fumarate (TDF) on Renal Function in Elderly Veterans
por: Yang, Dylan, et al.
Publicado: (2018)

Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
por: Wiriyatanakorn, Sirichai, et al.
Publicado: (2019)

999. Using the F/TDF Adherence-Efficacy Relationship to Calculate Background HIV incidence: Results from the DISCOVER trial
por: Glidden, David V, et al.
Publicado: (2020)

Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides
por: Mallon, Patrick W G, et al.
Publicado: (2021)

1288. Bone Safety Outcomes with F/TAF vs. F/TDF for PrEP in the DISCOVER Trial
por: Wohl, David, et al.
Publicado: (2019)

2491. Virologic Response of Switching Tenofovir Disoproxil Fumarate (TDF)-Based Regimen to Abacavir (ABC)-Based Regimen vs. Lopinavir/Ritonavir(LPV/r) Plus Lamivudine(3TC) in HIV-Infected Patients with TDF-Induced Nephrotoxicity at 24 Weeks: A Prospective, Open-Label, Randomized, Controlled Trial
por: Songumpai, Nopporn, et al.
Publicado: (2019)

1986. Switching to DOR/3TC/TDF Improves Renal Function and Decreases Lipid Levels in People Living With HIV: a Real-Life Multicentric Study
por: Micali, Cristina, et al.
Publicado: (2023)

Weight gain before and after switch from TDF to TAF in a U.S. cohort study
por: Mallon, Patrick WG, et al.
Publicado: (2021)

163. Infective Endocarditis in Qatar: Risk Factors, Clinical Characteristics, Microbiology, and Outcomes
por: Zaqout, Ahmed, et al.
Publicado: (2019)

Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV
por: Munderi, Paula, et al.
Publicado: (2019)

Risk of chronic kidney disease in people living with HIV by tenofovir disoproxil fumarate (TDF) use and baseline D:A:D chronic kidney disease risk score
por: Hsu, R, et al.
Publicado: (2020)

855. Persistence on F/TAF versus F/TDF for HIV Pre-Exposure Prophylaxis: A Real-World Evidence Analysis in the United States
por: Tao, Li, et al.
Publicado: (2021)

Smoking, female gender and PI use are associated with decreasing renal function in TDF-containing HAART
por: Uglietti, A, et al.
Publicado: (2010)

F163. STRUCTURAL AND FUNCTIONAL ALTERATIONS IN THE BRAIN DURING WORKING MEMORY IN MEDICATION-NAïVE PATIENTS AT CLINICAL HIGH-RISK FOR PSYCHOSIS
por: Brønnick, Kolbjørn, et al.
Publicado: (2018)

866. Adherence to F/TDF for PrEP in Dried Blood Spots and HIV Infection Rates: A Pooled Analysis of Global PrEP Studies
por: Liu, Albert, et al.
Publicado: (2021)

Identifying the role of PrimPol in TDF-induced toxicity and implications of its loss of function mutation in an HIV+ patient
por: Duong, Vincent N., et al.
Publicado: (2020)

S163. FEASIBILITY STUDY: MEASURES OF SLEEP AND PHYSICAL ACTIVITY IN PEOPLE WITH SCHIZOPHRENIA
por: Berry, Alexandra, et al.
Publicado: (2018)

Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis
por: Stellbrink, Hans-Juergen, et al.
Publicado: (2014)

Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States
por: Peng, Siyang, et al.
Publicado: (2014)

Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
por: Neukam, Karin, et al.
Publicado: (2014)

Local production of soluble CD163 in the spondyloarthropathic joint
por: Baeten, D, et al.
Publicado: (2003)

LB-7. Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF)
por: Sax, Paul, et al.
Publicado: (2020)

PS163. Serotonin Transporter Polymorphism in Severe Major Depressive Disorder in Indonesia
por: Arlisa, Wulandari, et al.
Publicado: (2016)

828. Short- and Long-Term Metabolic Changes in Virologically Suppressed Patients Switching from TDF to TAF Containing Antiretroviral Therapy
por: Schafer, Jason J, et al.
Publicado: (2021)

ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study
por: Podzamczer, Daniel, et al.
Publicado: (2014)

163. Automation of an Inpatient Provider Specific Antimicrobial Use Report
por: Weslander, Erin, et al.
Publicado: (2020)

1597. Randomized-Controlled Trial Evaluating The Outcome Between Switching to Tenofovir Disoproxil Fumarate(TDF)/Lamivudine(3TC)/Dolutegravir(DTG) Versus Maintaining The Current NNRTI Or Boosted-PI-containing Regimen in PLWH in Thailand – A Pilot Study from Single Center
por: Patamatamkul, Samadhi, et al.
Publicado: (2023)

163. Can Machine Learning Guide Antibiotic Initiation for Lower Respiratory Tract Infections?
por: Tang, Sarah, et al.
Publicado: (2023)

Deprescribing Medications that Increase the Risk of Falls in Older People: Exploring Doctors' Perspectives Using the Theoretical Domains Framework (TDF)
por: Kalim, Reham A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5qsk59snok7nb5daqpjlccoqsh